[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351507-105":59,"doc-detail-351507-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-leukocyte-antigen-g-in-solid-tumors-from-immunotolerance-to-immunotherapy","Human leukocyte antigen-G in solid tumors - from immunotolerance to immunotherapy","","Immune checkpoint-targeted immunotherapy has transformed cancer care, yet only a subset of patients benefits and limitations persist. Human leukocyte antigen-G (HLA-G) is presented as a novel immune checkpoint with restricted physiologic expression but broad tumor expression, where it promotes systemic immune suppression through multiple inhibitory receptor pathways. Since 2020, HLA-G-targeted preclinical and clinical studies have explored strategies across advanced solid cancers. This review highlights molecular features, receptor binding interactions, and translational challenges for clinical implementation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-leukocyte-antigen-g-in-solid-tumors-from-immunotolerance-to-immunotherapy/351507/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-leukocyte-antigen-g-in-solid-tumors-from-immunotolerance-to-immunotherapy/351507.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is HLA-G considered an attractive target for solid tumor immunotherapy?","Question",{"text":112,"@type":113},"HLA-G shows broad expression across tumors despite restricted physiologic expression, and it mediates systemic immune suppression via inhibitory receptors. It is also associated with poor prognosis, supporting tumor-site-agnostic targeting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key molecular aspects does the review emphasize about HLA-G?",{"text":117,"@type":113},"The review highlights updated molecular characteristics of HLA-G, including its structure and the interactions between HLA-G and its receptors. It also summarizes how these features relate to immunosuppressive functions.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the significance of HLA-G-targeted clinical trials since 2020?",{"text":121,"@type":113},"Clinical trials using different HLA-G-targeted strategies have been initiated and conducted for various advanced solid cancers. The review highlights the growing momentum from these efforts alongside preclinical findings.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351507,1790197151,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","TYPE Review  \nPUBLISHED 10 April 2026  \nDOI 10.3389/fimmu.2026.1696874  \nOPEN ACCESS  \nEDITED BY  \nJeffrey J. Pu,  \nTufts University, United States  \nREVIEWED BY  \nKaren Manoutcharian,  \nNational Autonomous University of Mexico, Mexico  \nJavier David Benitez Fuentes,  \nHospital General Universitario de Elche, Spain  \n*CORRESPONDENCE  \nWei-Hua Yan  \n[yanwh@enzemed.com](yanwh@enzemed.com)  \nRECEIVED 01 September 2025  \nREVISED 11 March 2026  \nACCEPTED 16 March 2026  \nPUBLISHED 10 April 2026  \nCITATION  \nLin A and Yan W-H (2026) Human leukocyte antigen-G in solid tumors:  \nfrom immunotolerance to immunotherapy.  \nFront. Immunol. 17:1696874 .  \ndoi: 10.3389/fimmu.2026.1696874  \nCOPYRIGHT  \n© 2026 Lin and Yan. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHuman leukocyte  \nantigen-G in solid tumors: from immunotolerance to immunotherapy  \nAifen Lin 1,2,3 and Wei-Hua Yan 2,3,4*  \n1 Biological Resource Center, Taizhou Hospital of Zhejiang Province, WenZhou Medical University, Linhai, Zhejiang, China, 2 Key Laboratory of Minimally Invasive Techniques and Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province, WenZhou Medical University, Linhai, Zhejiang, China, 3 Key Laboratory of Human Leukocyte Antigen (HLA-G) Research and Antibody Development of Taizhou, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, 4 Medical Research Center, Taizhou Hospital of Zhejiang Province, WenZhou Medical University, Linhai, Zhejiang, China  \nImmune checkpoint-targeted immunotherapy has achieved unprecedented success, yet its limitations remain evident. Human leukocyte antigen-G (HLAG), a novel immune checkpoint, exhibits restricted physiologic expression but is broadly expressed in various tumors, conferring systemic immune suppressive functions via different types of immune inhibitory receptors, and is associated with a poor prognosis for patients with cancer, making it an attractive tumor-siteagnostic candidate target for cancer immunotherapy. Since 2020, clinical trials employing different strategies of HLA-G-targeted immunotherapy for various advanced solid cancers have been conducted. Herein, the molecular characteristics of HLA-G, HLA-G-receptor binding interactions, and HLA-Gtargeted preclinical investigations and clinical trials for solid cancer immunotherapy are highlighted, and the challenges associated with translating these ﬁndings into clinical settings are also discussed.  \nKEYWORDS  \ncancer, human leukocyte antigen-G, immune checkpoint, immunotherapy, isoform, receptor  \nIntroduction  \nSince the ﬁrst immune checkpoint inhibitor (ICI) against cytotoxic T lymphocyteassociated protein 4 (CTLA-4) was approved by the US Food and Drug Administration (FDA) in 2011, unprecedented success has been achieved in the ﬁeld of immunotherapy for patients with cancer; however, limitations remain, such as the fact that only a subset of patients beneﬁt clinically (1, 2) . Inspired by these pioneering achievements, the exploration of novel ICIs to obtain better clinical beneﬁts is increasing. Among these novel ICIs, human leukocyte antigen-G (HLA-G) is well acknowledged (3) . HLA-G is a member of the nonclassical HLA class I antigens (HLA-E, HLA-F, HLA-G, and HLA-H) . Unlike the classical HLA class I antigens, which have been extensively investigated, the immunomodulatory roles and clinical signiﬁcance of the non-classical HLA class I antigens in cancer biology, particularly HLA-G, have garnered increasing attention (4) .  \nFrontiers in Immunology 01 [frontiersin.org]","cbCaignhmpff27fj","https://ap.wps.com/l/cbCaignhmpff27fj","pdf",2718263,15,"English","# Introduction\n## General features of HLA-G\n# Immune checkpoint-targeted immunotherapy context\n# HLA-G molecular characteristics and receptor binding\n# HLA-G-targeted preclinical studies and clinical trials\n# Translational challenges","[{\"question\":\"Why is HLA-G considered an attractive target for solid tumor immunotherapy?\",\"answer\":\"HLA-G shows broad expression across tumors despite restricted physiologic expression, and it mediates systemic immune suppression via inhibitory receptors. It is also associated with poor prognosis, supporting tumor-site-agnostic targeting.\"},{\"question\":\"What key molecular aspects does the review emphasize about HLA-G?\",\"answer\":\"The review highlights updated molecular characteristics of HLA-G, including its structure and the interactions between HLA-G and its receptors. It also summarizes how these features relate to immunosuppressive functions.\"},{\"question\":\"What is the significance of HLA-G-targeted clinical trials since 2020?\",\"answer\":\"Clinical trials using different HLA-G-targeted strategies have been initiated and conducted for various advanced solid cancers. The review highlights the growing momentum from these efforts alongside preclinical findings.\"}]","Human leukocyte antigen-G in solid tumors - from immunotolerance to immunotherapy | PDF",1790094487,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f21280706c482eed6db69016fa44be7c.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b7b7c060f9a484269e381f1ef80f2b52.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b18fb2f8a79f631dd68a409d4aa6501c.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/167fbebb4c71d8821c051c806f7f6acf.webp",980,1385]